241 related articles for article (PubMed ID: 16776850)
1. The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.
Têtu B; Brisson J; Wang CS; Lapointe H; Beaudry G; Blanchette C; Trudel D
Breast Cancer Res; 2006; 8(3):R28. PubMed ID: 16776850
[TBL] [Abstract][Full Text] [Related]
2. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
3. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
7. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
Swellam M; Arab LR; Bushnak HA
IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
[TBL] [Abstract][Full Text] [Related]
9. Expression of the metalloproteases MMP-1, MMP-2, MMP-3, MMP-9, MMP-11, TIMP-1 and TIMP-2 in angiocentric midfacial lymphomas.
Meneses-García A; Betancourt AM; Abarca JH; Montes AB; Roa LS; Ruíz-Godoy L
World J Surg Oncol; 2008 Oct; 6():114. PubMed ID: 18954439
[TBL] [Abstract][Full Text] [Related]
10. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
11. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
12. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
13. Significance of matrix metalloproteinases and tissue inhibitors of metalloproteinase expression in the recurrence of superficial transitional cell carcinoma of the bladder.
Hara I; Miyake H; Hara S; Arakawa S; Kamidono S
J Urol; 2001 May; 165(5):1769-72. PubMed ID: 11342973
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
19. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer.
Zhang M; Teng XD; Guo XX; Li ZG; Han JG; Yao L
Breast; 2013 Jun; 22(3):330-4. PubMed ID: 22995648
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
